Drug repurposing as a source of innovative therapies in pancreatic cancer

Objectives Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is one of the deadliest tumors with 5-year survival rates still under 10%. Few drugs have been able to make significant improvements in patient outcomes and, albeit that there is a pipeline of new agents, many fail in phase 2/3 clinical trials. Drug repurposing, an alternative development pathway, seeks to reuse existing drugs as the source of new treatment options. Repurposing benefits from existing data on safety, dosing and clinical experience.

Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Pan Pantziarka, Gauthier Bouche, Ilse Rooman Tags: 8. Pancreatic Cancer I Source Type: research